金斯瑞生物科技拟分拆蓬勃生物赴港交所主板独立上市

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock
Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy
or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance
upon the whole or any part of the contents of this announcement.
This announcement appears for information purposes only and does not constitute or form part of any prospectus,
invitation or offer to acquire, purchase or subscribe for any securities nor shall it or any part of it form the basis of
or be relied upon in connection with any contract or commitment whatsoever. In particular, this announcement does
not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong or elsewhere.

Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)
INSIDE INFORMATION
PROPOSED SPIN-OFF AND SEPARATE LISTING OF PROBIO TECHNOLOGY
LIMITED
This announcement is made by the board of directors (the “Board”) of Genscript Biotech
Corporation (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09
of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the
“Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part
XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and
Practice Note 15 (“PN15”) of the Listing Rules.
THE PROPOSED SPIN-OFF
The Board hereby announces that the Company proposes to spin-off and separately list the shares
of Probio Technology Limited (“ProBio”), an indirect non-wholly-owned subsidiary of the
Company which operates the Group’s Biologics and Advanced Therapy Contract Research,
Development, and Manufacturing Organization services, on the Main Board of the Stock Exchange
(the “Proposed Spin-off”).
In connection with the Proposed Spin-off, the Company submitted an application to the Stock
Exchange in compliance with PN15. On 14 August 2026, the Listing Committee confirmed that the
Company may proceed with the Proposed Spin-off.
Details of the Proposed Spin-off have yet to be finalized. Upon completion of the Proposed Spinoff, the Company will continue to hold a controlling interest in ProBio, which will remain as a
subsidiary of the Company, and its financial results will continue to be consolidated into the
financial statements of the Group.

1

GENERAL
Pursuant to the requirements under PN15, the Company is required to have due regard to the
interests of its existing shareholders by providing them with an assured entitlement to the shares to
be issued by ProBio (the “Assured Entitlement”) by way of a preferential application if the
Proposed Spin-off proceeds, subject to certain conditions, including the approval of the Stock
Exchange and other regulatory authorities for the Proposed Spin-off. The terms of such Assured
Entitlement have not been finalized but in any event all the qualifying shareholders of the Company
will be treated equally. The Company will make further announcements in this regard as and when
appropriate pursuant to the Listing Rules.
The Proposed Spin-off, if materialized, will constitute a deemed disposal of the interest in a
subsidiary of the Company under Rule 14.29 of the Listing Rules. The Company will comply with
the applicable requirements of Chapter 14 of the Listing Rules and the requirements under PN15 as
and when appropriate.
As the Proposed Spin-off is subject to, among other things, final approval by the Listing
Committee, market conditions, and other considerations, the Proposed Spin-off may or may
not materialize. Shareholders and other investors are advised to exercise caution when dealing
in the securities of the Company.
By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 4 September 2026

As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang,
Dr. Li Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse
Galdes, Mr. Andy Cheung, Mr. Ethan Pan, Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.

2

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責，對其準確
性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內
容而引致的任何損失承擔任何責任。
本公告僅供參考，並不構成收購、購買或認購任何證券之招股章程、邀請或要約或屬於其中一部份，其或
其任何部份概不構成任何合約或承諾之基礎或依據。具體而言，本公告並不構成亦非在香港或其他地方出
售證券之要約或要約購買證券之招攬。

Genscript Biotech Corporation
（於開曼群島註冊成立的有限公司）
（股份代號：1548）

內幕消息
PROBIO TECHNOLOGY LIMITED 建議分拆及獨立上市
本公告由金斯瑞生物科技股份有限公司（「本公司」，連同其附屬公司，稱爲「本集團」）董
事會（「董事會」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09 條與
香港法例第 571 章證券及期貨條例第 XIVA 部內幕消息條文（定義見上市規則）以及上市規
則第 15 項應用指引（「第 15 項應用指引」）而作出。
建議分拆
董事會謹此宣佈，本公司建議將 Probio Technology Limited（「蓬勃生物」，為本公司的間接
非全資附屬公司，負責本集團的生物製劑及先進療法合約研究、開發及生產組織服務）分拆
並將其股份在聯交所主板獨立上市（「建議分拆」）。
就建議分拆而言，本公司已根據第 15 項應用指引向聯交所提交申請。於 2026 年 8 月 14
日，上市委員會確認本公司可繼續推行建議分拆。
有關建議分拆的詳情尚待落實。於建議分拆完成後，本公司將繼續持有蓬勃生物的控股權益，
其仍將為本公司的附屬公司，其財務業績將繼續合併入本集團的財務報表中。

1

一般資料
根據第 15 項應用指引的規定，倘若建議分拆得以推行，本公司須適當考慮現有股東的權益，
並於包括聯交所及其他監管機構批准建議分拆在内的若干條件規限下，通過優先申請方式，
向股東提供蓬勃生物所將發行之股份的保證配額（「保證配額」）。保證配額的條款尚未落實，
但無論如何，本公司所有合資格股東將獲平等待遇。本公司將按上市規則都規定，於適當時
候就此刊發進一步公告。
倘建議分拆得以落實，將構成本公司於上市規則第 14.29 條項下視作處置於本公司附屬公司
的權益。屆時本公司將遵守上市規則第 14 章及第 15 項應用指引項下的適用規定。

由於建議分拆須視乎（其中包括）上市委員會的最終批准、市場狀況及其他考慮因素而定，
建議分拆可能會或不會落實。股東及其他投資者務請在買賣本公司證券時謹慎行事。

承董事會命
Genscript Biotech Corporation

主席及執行董事
孟建革

香港，2026 年 9 月 4 日

於本公告日期，執行董事為孟建革先生、章方良博士、朱力博士及王燁女士；及獨立非執行
董事為 Alphonse Galdes 博士、張耀樑先生、潘九安先生、John Quelch 博士、Ross Grossman
博士及施晨陽博士。

2